Aberrant Splicing of SDHC in Families With Unexplained Succinate Dehydrogenase-Deficient Paragangliomas

• Published in: Journal of the Endocrine Society Vol. 4; no. 12; p. bvaa071
• Main Authors: De Sousa, Sunita M C, Toubia, John, Hardy, Tristan S E, Feng, Jinghua, Wang, Paul, Schreiber, Andreas W, Geoghegan, Joel, Hall, Rachel, Rawlings, Lesley, Buckland, Michael, Luxford, Catherine, Novos, Talia, Clifton-Bligh, Roderick J, Poplawski, Nicola K, Scott, Hamish S, Torpy, David J
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.12.2020
• Subjects: Cabergoline; Clinical s; Codon; DNA sequencing; Gene mutations; Genes; Genetic aspects; Genetic screening; Nucleotide sequencing; Tumors; Australia; intronic mutation; whole-exome sequencing; paraganglioma; succinate dehydrogenase; SDHC
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvaa071

Abstract Context Germline mutations in the succinate dehydrogenase genes (SDHA/B/C/D, SDHAF2—collectively, “SDHx”) have been implicated in paraganglioma (PGL), renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST), and pituitary adenoma (PA). Negative SDHB tumor staining is indicative of SDH-deficient tumors, usually reflecting an underlying germline SDHx mutation. However, approximately 20% of individuals with SDH-deficient tumors lack an identifiable germline SDHx mutation. Methods We performed whole-exome sequencing (WES) of germline and tumor DNA followed by Sanger sequencing validation, transcriptome analysis, metabolomic studies, and haplotype analysis in 2 Italian-Australian families with SDH-deficient PGLs and various neoplasms, including RCC, GIST, and PA. Results Germline WES revealed a novel SDHC intronic variant, which had been missed during previous routine testing, in 4 affected siblings of the index family. Transcriptome analysis demonstrated aberrant SDHC splicing, with the retained intronic segment introducing a premature stop codon. WES of available tumors in this family showed chromosome 1 deletion with loss of wild-type SDHC in a PGL and a somatic gain-of-function KIT mutation in a GIST. The SDHC intronic variant identified was subsequently detected in the second family, with haplotype analysis indicating a founder effect. Conclusions This is the deepest intronic variant to be reported among the SDHx genes. Intronic variants beyond the limits of standard gene sequencing analysis should be considered in patients with SDH-deficient tumors but negative genetic test results.